Stock KURA KURA ONCOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Kura Oncology, Inc.

Equities

KURA

US50127T1097

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-09 EDT 		5-day change 1st Jan Change
20.77 USD +1.10% Intraday chart for Kura Oncology, Inc. +0.87% +44.44%
05-02 Transcript : Kura Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024
05-02 Kura Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kura Oncology to Participate in Bank of America Securities Healthcare Conference
AQ
KURA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
AQ
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Kura Oncology : Corporate Presentation - May 2024
PU
Kura Oncology: Q1 Earnings Snapshot
AQ
Kura Oncology Reports First Quarter 2024 Financial Results
AQ
Kura Oncology to Report First Quarter 2024 Financial Results
AQ
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
AQ
Kura Oncology to Participate in Stifel Targeted Oncology Forum
AQ
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
AQ
KURA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)
AQ
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Kura Oncology: Q4 Earnings Snapshot
AQ
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia
AQ
Kura Oncology to Participate in Three Upcoming Investor Conferences
AQ
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
AQ
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KURA Stock
  4. News Kura Oncology, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW